
|Articles|March 1, 2008
Accommodating IOL's new design shows benefits
Results of a multicenter FDA clinical trial of a fourth-generation version of an accommodating IOL (crystalens HD-100, eyeonics/Bausch & Lomb) demonstrate that the lens provides excellent uncorrected visual acuity at all distances that exceeds those of previous versions and without causing loss of contrast sensitivity.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
How AI is reshaping ophthalmology in 2025 and beyond
2
Glaucoma 2026: Which emerging technologies will change practice?
3
Molecular insights and clinical experience: Extending anti-VEGF durability
4
8 things to know about aflibercept 8 mg for retinal vascular disease
5












































